Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 687 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vector Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo

NCT02598388
View directory record Official record
Conditions
Hemorrhagic Fever, Ebola
Interventions
Ad26.ZEBOV, MVA-BN-Filo, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 70 Years
Enrollment
578 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 23, 2026, 2:24 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)

NCT05477524
View directory record Official record
Conditions
Lyme Disease
Interventions
VLA15, Saline
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
5 Years and older
Enrollment
12,546 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
82
States / cities
Essex, Connecticut • Ledyard Center, Connecticut • New London, Connecticut + 67 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 23, 2026, 2:24 PM EDT
Completed Phase 2 Interventional Results available

Choroideremia Gene Therapy Clinical Trial

NCT02553135
View directory record Official record
Conditions
Choroideremia
Interventions
Injection of AAV2-REP1 (10e11 vg)
Biological
Lead sponsor
Byron Lam
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 23, 2026, 2:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults

NCT04064905
View directory record Official record
Conditions
Zika Virus
Interventions
mRNA-1893, Placebo
Biological · Other
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
3
States / cities
Omaha, Nebraska • Austin, Texas • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 23, 2026, 2:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dengue 4 Human Infection Model (Dengue CVD 11000; DHIM-4)

NCT05268302
View directory record Official record
Conditions
Dengue
Interventions
Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose, Dengue 4 Live Virus Human Challenge (DENV-4-LVHC) - Low Dose - Homologous Rechallenge
Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 23, 2026, 2:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Investigation of Infections Due to Leishmanial Parasites

NCT00001169
View directory record Official record
Conditions
Leishmaniasis, Leishmaniasis, Visceral
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1979 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 2:24 PM EDT
Completed Phase 1 Interventional

Treatment of SCID Due to ADA Deficiency With Autologous Transplantation of Cord Blood or Hematopoietic CD 34+ Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector

NCT02022696
View directory record Official record
Conditions
Adenosine Deaminase Deficiency, ADA-SCID
Interventions
Lentiviral Gene Transfer
Genetic
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
1 Year to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Oct 23, 2026, 2:24 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas

NCT04917861
View directory record Official record
Conditions
Zika Virus
Interventions
mRNA-1893, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
808 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
3
States / cities
Sioux City, Iowa • Lenexa, Kansas • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 23, 2026, 2:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Trial of Measles Vectored Chikungungya Vaccine

NCT03028441
View directory record Official record
Conditions
Chikungunya Virus Infection
Interventions
Placebo, VRC-CHKVLP059-00-VP
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
3
States / cities
Atlanta, Georgia • Iowa City, Iowa • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 23, 2026, 2:24 PM EDT
Terminated Early Phase 1 Interventional

Gene Transfer for HIV Using Autologous T Cells

NCT01153646
View directory record Official record
Conditions
HIV-1 Infection
Interventions
pHIV7-shI-TAR-CCR5RZ treated CD4 cells
Genetic
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2011 · Synced Oct 23, 2026, 2:24 PM EDT
Completed Early Phase 1 Interventional Results available

Autologous CD4 T-Cells in HIV (C34-CXCR4)

NCT03020524
View directory record Official record
Conditions
Hiv
Interventions
Autologous CD4 T-Cells
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Oct 23, 2026, 2:24 PM EDT
Active, not recruiting Phase 1 Interventional

Gene Transfer for Sickle Cell Disease

NCT03282656
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
single infusion of autologous bone marrow derived CD34+ HSC cells transduced with the lentiviral vector containing a short-hairpin RNA targeting BCL11a
Biological
Lead sponsor
David Williams
Other
Eligibility
3 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 23, 2026, 2:24 PM EDT
Completed Phase 1 Interventional

Phase I Trial of Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations

NCT00481546
View directory record Official record
Conditions
Amaurosis of Leber, Retinal Diseases
Interventions
rAAV2-CBSB-hRPE65
Genetic
Lead sponsor
University of Pennsylvania
Other
Eligibility
8 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
2
States / cities
Gainesville, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 23, 2026, 2:24 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents

NCT03110770
View directory record Official record
Conditions
Zika Virus, Zika Virus Infection, Virus Diseases, Flavivirus Infections, Flaviviral Diseases, Flaviviridae Infections, RNA Virus Infections
Interventions
VRC-ZKADNA090-00-VP, VRC-PBSPLA043-00-VP
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
15 Years to 35 Years
Enrollment
2,428 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
3
States / cities
Miami, Florida • Edinburg, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 23, 2026, 2:24 PM EDT
Completed Phase 1Phase 2 Interventional

Treating Post-Lyme Disease Syndrome With Acetogenins

NCT04078841
View directory record Official record
Conditions
Post-Lyme Disease Syndrome (PLDS)
Interventions
ReaLife+ (RLP), Inert Brown powder
Dietary Supplement · Other
Lead sponsor
Optimal Health Research
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 23, 2026, 2:24 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations

NCT00001539
View directory record Official record
Conditions
Lyme Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 99 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1996
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 2:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Studies of AQ-13, a Candidate Aminoquinoline Antimalarial, in Comparison With Chloroquine

NCT00323375
View directory record Official record
Conditions
Malaria
Interventions
AQ-13, Chloroquine (CQ) Treatment
Drug
Lead sponsor
Tulane University Health Sciences Center
Other
Eligibility
21 Years to 45 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2005
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 23, 2026, 2:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine

NCT01072786
View directory record Official record
Conditions
Dengue
Interventions
TetraVax-DV Vaccine-Admixture 1, TetraVax-DV Vaccine-Admixture 2, TetraVax-DV Vaccine-Admixture 3, TetraVax-DV Vaccine-Admixture 4, Placebo, TetraVax-DV Vaccine-Admixture 5
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 23, 2026, 2:24 PM EDT
Terminated Not applicable Interventional Results available

Meditation and Stretching for Post Treatment Lyme Disease Syndrome

NCT02344537
View directory record Official record
Conditions
Post Treatment Lyme Disease Syndrome
Interventions
Kundalini Yoga
Behavioral
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Southport, Connecticut • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Oct 23, 2026, 2:24 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Defining Skin Immunity of a Bite of Key Insect Vectors in Humans

NCT03641339
View directory record Official record
Conditions
Zika, Dengue, Malaria, Chikungunya, Leishmaniasis
Interventions
One vector feeding, Four vector feeding
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Oct 23, 2026, 2:24 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S

NCT01556945
View directory record Official record
Conditions
Malaria, Falciparum
Interventions
FMP1/AS02, RTS,S/AS02, AS02 adjuvant alone, Malaria challenge
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2001
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated May 2, 2014 · Synced Oct 23, 2026, 2:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Adenovirus Vaccine for Malaria

NCT00371189
View directory record Official record
Conditions
Plasmodium Falciparum Infection
Interventions
Placebo, Ad35.CS.01 Circumsporozoite Malaria Vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
2
States / cities
Stanford, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 23, 2026, 2:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Immunization Via Mosquito Bite With Radiation-attenuated Sporozoites

NCT01994525
View directory record Official record
Conditions
Malaria
Interventions
PfRAS, Placebo, Challenge
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 23, 2026, 2:24 PM EDT
Recruiting No phase listed Observational

Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders

NCT07683104
View directory record Official record
Conditions
Trisomy 8 Mosaicism, Trisomy 8 Associated Autoinflammatory Disease, Mucosal Ulcerations
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 99 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2056
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 23, 2026, 2:24 PM EDT